Trial · NCT01831232
Adverse events13
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 13 of 13
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Febrile neutropenia Grade 3 | Blood and lymphatic system disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 17 | 24 | 17 |
| other | Febrile neutropenia Grade 4 | Blood and lymphatic system disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 1 | 24 | 1 |
| other | Rash Grade 3 | Skin and subcutaneous tissue disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 3 | 24 | 3 |
| other | Hand-foot syndrome Grade 3 | Skin and subcutaneous tissue disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 2 | 24 | 2 |
| other | Septic shock (Grade 4) | Infections and infestations | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 1 | 24 | 1 |
| other | Diarrhea Grade 3 | Gastrointestinal disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 6 | 24 | 6 |
| other | Nausea/Vomiting | Gastrointestinal disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 4 | 24 | 4 |
| other | Mucositis | Gastrointestinal disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 3 | 24 | 3 |
| other | Transaminitis Grade 3 | Investigations | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 2 | 24 | 2 |
| other | Colon pneumatosis Grade 3 | Gastrointestinal disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 1 | 24 | 1 |
| other | GI bleeding Grade 3 | Gastrointestinal disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 1 | 24 | 1 |
| other | Tumor lysis syndrome Grade 3 | Metabolism and nutrition disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 1 | 24 | 1 |
| serious | Multi organ failure secondary to sepsis | General disorders | Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine) | 2 | 24 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01831232/events